Enterprise Value

3.516B

Cash

690.9M

Avg Qtr Burn

-52.58M

Short % of Float

13.95%

Insider Ownership

55.53%

Institutional Own.

48.46%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Batoclimab (IMVT-1401) Details
Myasthenia gravis

Big Mover™

Susp. Mover™

Phase 3

Data readout

Batoclimab (IMVT-1401) Details
Chronic inflammatory disorder

Phase 2b

Data readout

Phase 2

Update

IMVT-1402 Details
Autoimmune disease, Warm autoimmune hemolytic anemia

Phase 1

Update

Batoclimab (IMVT-1401) Details
Warm autoimmune hemolytic anemia

Failed

Discontinued